SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Purchased by AMH Equity Ltd

AMH Equity Ltd lifted its position in SCYNEXIS, Inc. (NASDAQ:SCYX) by 134.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 550,400 shares of the company’s stock after purchasing an additional 315,612 shares during the quarter. SCYNEXIS makes up 1.1% of AMH Equity Ltd’s investment portfolio, making the stock its 18th biggest holding. AMH Equity Ltd owned about 1.48% of SCYNEXIS worth $1,227,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. TFB Advisors LLC acquired a new stake in SCYNEXIS during the 4th quarter worth approximately $27,000. Park Avenue Securities LLC acquired a new stake in SCYNEXIS during the 3rd quarter worth approximately $32,000. Ritholtz Wealth Management acquired a new stake in SCYNEXIS during the 3rd quarter worth approximately $42,000. O Shaughnessy Asset Management LLC acquired a new stake in SCYNEXIS during the 3rd quarter worth approximately $94,000. Finally, Chicago Partners Investment Group LLC lifted its position in SCYNEXIS by 30.6% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 53,321 shares of the company’s stock worth $122,000 after acquiring an additional 12,492 shares during the period. 54.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SCYX has been the subject of a number of recent research reports. StockNews.com cut SCYNEXIS from a “buy” rating to a “hold” rating in a research report on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of SCYNEXIS in a research note on Monday, April 1st.

SCYNEXIS Stock Performance

Shares of SCYX stock opened at $1.54 on Friday. The company has a market cap of $58.14 million, a price-to-earnings ratio of 1.17 and a beta of 1.57. The stock has a 50 day simple moving average of $1.56 and a 200-day simple moving average of $1.74. SCYNEXIS, Inc. has a 12-month low of $1.35 and a 12-month high of $3.87. The company has a current ratio of 6.26, a quick ratio of 6.26 and a debt-to-equity ratio of 0.17.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.